Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.42 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951179 | 0.88 | KCNQ3 (0.44) | KCNQ3KCNQ2KCNQ5VCAM1 | |
| SCHEMBL14026775 | 0.86 | KDM4E (0.36) | KCNQ3KCNQ2METAXLVCAM1 | |
| SCHEMBL2955364 | 0.86 | VCAM1 (0.36) | KCNQ3KCNQ2METAXLVCAM1 | |
| SCHEMBL2947872 | 0.84 | GCK (0.38) | HPGDKDM4EHSD17B10 | |
| SCHEMBL2949211 | 0.83 | VCAM1 (0.34) | KCNQ3KCNQ2METAXLVCAM1 | |
| SCHEMBL14026777 | 0.83 | KCNQ3 (0.35) | KCNQ3KCNQ2KCNQ5VCAM1 | |
| SCHEMBL8292440 | 0.82 | SLC9A1 (0.57) | — | |
| SCHEMBL8271434 | 0.81 | VCAM1 (0.37) | KCNQ3KCNQ2KCNQ5VCAM1HPGD | |
| SCHEMBL8269971 | 0.81 | VCAM1 (0.31) | KCNQ3KCNQ2METAXLVCAM1 | |
| SCHEMBL5087619 | 0.81 | SLC9A1 (0.48) | VCAM1KDM4ESMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763661-B2 | Ortho-substituted pentafluorosulfanyl benzenes, method for the production thereof and their use as synthesis intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7763661-B2 | Ortho-substituted pentafluorosulfanyl benzenes, method for the production thereof and their use as synthesis intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7763661-B2 | Ortho-substituted pentafluorosulfanyl benzenes, method for the production thereof and their use as synthesis intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| US-20070259943-A1 | ORTHO-SUBSTITUTED PENTAFLUOROSULFANYL BENZENES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS SYNTHESIS INTERMEDIATES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259943-A1 | ORTHO-SUBSTITUTED PENTAFLUOROSULFANYL BENZENES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS SYNTHESIS INTERMEDIATES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259943-A1 | ORTHO-SUBSTITUTED PENTAFLUOROSULFANYL BENZENES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS SYNTHESIS INTERMEDIATES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259943-A1 | ORTHO-SUBSTITUTED PENTAFLUOROSULFANYL BENZENES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS SYNTHESIS INTERMEDIATES | PFAS, DDT, PNPO | KCNQ3 1864/4885KCNQ2 1230/4885KCNQ5 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.